ADAMTS13 and thrombotic thrombocytopenic purpura: In addition, the United States Food and drug administration approved the first and only recombinant ADAMTS-13 enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura [36,37].